Definium Therapeutics DFTX
$28.34 −$1.14 (-3.87%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $28.05 -1.02%
Open$29.14
Prev close$29.48
Day range$28.18 – $29.51
Volume3.24M
Market cap$3.88B
P/E (TTM)–
Dividend yield–
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$0.00
Operating profit-$72.28M-58.3% YoY
Net profit-$50.96M+24.2% YoY
Diluted EPS-$0.46+41.0% YoY
Free cash flow-$52.98M-79.2% YoY
Operating cash flow-$52.98M
Revenue, last 8 quarters
Net profit, last 8 quarters
Diluted EPS by quarter
Free cash flow by quarter
Annual revenue
Profitability & balance sheet
Return on equity-61.4%
Return on assets-51.5%
Return on invested capital-60.1%
Current ratio15.53
Liabilities / assets9.9%
Cash & investments$1.05B
Total debt$36.66M
Net cash (debt)$1.01B
Income statement
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Operating Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Expense | $72.28M | $75.08M | $59.22M | $166.31M | $47.58M |
| Selling and Admin Expenses | $26.14M | $26.41M | $17.74M | $48.64M | $14.06M |
| -General & Admin Expense | $26.14M | $26.41M | $17.74M | $48.64M | $14.06M |
| Research & Development | $46.14M | $48.67M | $41.48M | $117.67M | $33.52M |
| Operating Profit | -$72.28M | -$75.08M | -$59.22M | -$166.31M | -$47.58M |
| Net Non-Operating Interest Income (Expense) | $8.99M | $2.35M | $2.21M | $5.48M | $2.22M |
| Non-Operating Interest Income | $10.14M | $3.59M | $3.46M | $10.96M | $3.49M |
| Non-Operating Interest Expense | $1.15M | $1.23M | $1.25M | $5.48M | $1.27M |
| Other Income (Expense) | $12.33M | -$86.26M | -$20.09M | -$22.96M | -$5.08M |
| Gain on Sale of Security | $12.33M | -$86.26M | -$20.09M | -$22.96M | -$5.08M |
| Pretax Profit | -$50.96M | -$158.99M | -$77.10M | -$183.79M | -$50.44M |
| Net Profit | -$50.96M | -$158.99M | -$77.10M | -$183.79M | -$50.44M |
| Profit from Continuing Operations | -$50.96M | -$158.99M | -$77.10M | -$183.79M | -$50.44M |
| Net Income to Parent Company | -$50.96M | -$158.99M | -$77.10M | -$183.79M | -$50.44M |
| Net Income to Common Stockholders | -$50.96M | -$158.99M | -$77.10M | -$183.79M | -$50.44M |
| Basic EPS | -$0.37 | -$1.44 | -$0.71 | -$2.06 | -$0.50 |
| Diluted EPS | -$0.46 | -$1.44 | -$0.71 | -$2.06 | -$0.50 |
| Special Income (Charges) | – | – | – | $0.00 | $0.00 |
Balance sheet
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Assets | $1.07B | $1.11B | $401.29M | $440.10M | $440.10M |
| Total Current Assets | $1.05B | $1.09B | $380.56M | $419.32M | $419.32M |
| Cash and Cash Equivalents & Short-Term Investments | $1.05B | $1.08B | $373.42M | $411.59M | $411.59M |
| -Cash and Cash Equivalents | $241.15M | $655.27M | $262.52M | $257.84M | $257.84M |
| -Short Term Investments | $805.70M | $428.61M | $110.90M | $153.76M | $153.76M |
| Other Current Assets | $4.91M | $8.22M | $7.14M | $7.73M | $7.73M |
| Total Non-Current Assets | $22.52M | $20.80M | $20.73M | $20.78M | $20.78M |
| Goodwill and Other Intangible Assets | $19.92M | $19.92M | $19.92M | $19.92M | $19.92M |
| -Goodwill | $19.92M | $19.92M | $19.92M | $19.92M | $19.92M |
| Other Non-Current Assets | $2.61M | $880,000.00 | $812,000.00 | $862,000.00 | $862,000.00 |
| Total Liabilities | $106.25M | $194.22M | $122.44M | $107.77M | $107.77M |
| Total Current Liabilities | $67.73M | $157.20M | $81.11M | $66.70M | $66.70M |
| Payables | $9.28M | $6.97M | $7.13M | $5.35M | $5.35M |
| -Accounts Payable | $9.28M | $6.97M | $7.13M | $5.35M | $5.35M |
| Current Accrued Expenses | $18.48M | $17.12M | $17.10M | $10.98M | $10.98M |
| Other Current Liabilities | $21.33M | $113.02M | $49.47M | $40.91M | $40.91M |
| Total Non-Current Liabilities | $38.52M | $37.02M | $41.33M | $41.08M | $41.08M |
| Long Term Debt and Capital Lease Obligation | $36.66M | $36.47M | $40.77M | $40.58M | $40.58M |
| -Long Term Debt | $36.66M | $36.47M | $40.77M | $40.58M | $40.58M |
| Other Non-Current Liabilities | $1.86M | $549,000.00 | $559,000.00 | $496,000.00 | $496,000.00 |
| Total Equity | $968.03M | $918.68M | $278.85M | $332.33M | $332.33M |
| Stockholders' Equity | $968.03M | $918.68M | $278.85M | $332.33M | $332.33M |
| Capital Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| -Common Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Additional Paid-In Capital | $1.84B | $1.74B | $937.80M | $913.91M | $913.91M |
| Retained Earnings | -$869.72M | -$818.76M | -$659.77M | -$582.67M | -$582.67M |
| Gains/Losses Not Affecting Retained Earnings | -$829,000.00 | $417,000.00 | $824,000.00 | $1.09M | $1.09M |
Cash flow
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$52.98M | -$52.78M | -$42.63M | -$131.56M | -$42.98M |
| Net cash flow from continuing operations | -$52.98M | -$52.78M | -$42.63M | -$131.56M | -$42.98M |
| Net Income from Continuing Operations | -$50.96M | -$158.99M | -$77.10M | -$183.79M | -$50.44M |
| Gain/Loss from Continuing Operations | -$12.34M | $86.22M | $20.05M | $22.83M | $5.06M |
| Other Non-Cash Items | -$363,000.00 | $4.66M | $1.25M | $1.69M | $632,000.00 |
| Change in Working Capital | $2.92M | $6.28M | $5.45M | $9.44M | -$2.29M |
| -Change in Prepaid Assets | $2.49M | -$264,000.00 | $585,000.00 | $152,000.00 | -$2.44M |
| -Change in Payables and Accrued Expense | $3.81M | $6.69M | $4.77M | $9.30M | -$1.84M |
| -Change in Other Current Assets | -$21,000.00 | -$133,000.00 | $118,000.00 | $30,000.00 | $17,000.00 |
| -Change in Other Current Liabilities | -$59,000.00 | -$10,000.00 | -$29,000.00 | -$40,000.00 | -$23,000.00 |
| Net cash flow from investing | -$372.80M | -$316.74M | $42.00M | -$151.61M | $34.98M |
| Net Cash Flow from Continuing Investing Activities | -$372.80M | -$316.74M | $42.00M | -$151.61M | $34.98M |
| Net Investment Purchase and Sale | -$372.80M | -$316.74M | $42.00M | -$151.61M | $34.98M |
| Financing Cash Flow | $11.66M | $762.27M | $5.31M | $267.27M | $245.87M |
| Net Cash Flow from Continuing Financing Activities | $11.66M | $762.27M | $5.31M | $267.27M | $245.87M |
| Net Issuance Payments Of Debt | $0.00 | – | – | $20.00M | $0.00 |
| Net Common Stock Issuance | $0.00 | $804.72M | $276,000.00 | $258.86M | $258.86M |
| Proceeds from Stock Option Exercised | $18.17M | -$2.69M | $5.03M | $1.04M | -$811,000.00 |
| Net Other Financing Charges | -$6.50M | – | – | -$12.63M | -$12.18M |
| Ending Cash Balance | $241.15M | $655.27M | $262.52M | $257.84M | $257.84M |
| Net Change in Cash | -$414.11M | $392.75M | $4.68M | -$15.90M | $237.88M |
| Beginning Cash Balance | $655.27M | $262.52M | $257.84M | $273.74M | $19.96M |
| Effect of Exchange Rate Changes | -$5,000.00 | -$1,000.00 | $3,000.00 | -$7,000.00 | $1,000.00 |
| Free Cash Flow | -$52.98M | -$52.78M | -$42.63M | -$131.56M | -$42.98M |
| Depreciation & Depletion & Amortization | – | – | – | $0.00 | $0.00 |
No comments yet — be the first to weigh in on DFTX.
Sign in to join the discussion.